Related coverage linked through entity extraction aliases.
Aug 21, 2026
Moderna and Merck's personalized mRNA cancer vaccine, intismeran autogene, showed promising Phase 3 results in preventing melanoma recurrence. Combined with Keytruda, it cut recurrence risk by half and reduced spread by 59% in earlier data. The treatment could reach patients within two years pending regulatory approval.
Aug 21, 2026
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
Aug 21, 2026
IceCure Medical's ProSense cryoablation system gains IRB approval for the ChoICE post-marketing study in low-risk breast cancer, with patient enrollment expected soon. Additionally, Thomas Hospital in Alabama becomes the first facility in the state to install ProSense, with procedures starting this month.
Aug 20, 2026
Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
Aug 19, 2026
A Chest study finds that respiratory or red flag symptoms at baseline increase the likelihood of lung cancer diagnosis within one year after screening. A Nature study identifies glucocorticoid-related genes with causal links to non-small cell lung cancer and constructs a multi-omics prognostic model.
Aug 18, 2026
Michelle, a mental health therapist, was diagnosed with stage 4 lung cancer and given 24 months to live. Through yoga and meditation, she shifted her mindset and is now thriving six years after diagnosis, with tumors continuing to shrink.
Aug 05, 2026
Major oncology conferences in 2026 include the IASLC World Conference on Lung Cancer in Seoul, the APPOS CAR T-cell therapy dinner in Los Angeles, and the ACP/UKSMO Annual Conference in Birmingham. The events will cover thoracic oncology research, CAR T-cell toxicity management, and medical oncology workforce development.
Aug 02, 2026
Recent studies show microbiome modulation boosts chemotherapy accumulation, peptide-based mRNA vaccines shrink neuroblastoma tumors by 70%, and engineered LNPs enhance lymph node delivery while cutting side effects.
Jun 21, 2026
A 2025 systematic review of 561,850 refugees reveals substantial cancer burden variation and barriers to care. Advanced-stage diagnosis is common, and UNHCR funding gaps in Jordan highlight resource limits.
May 22, 2026
Hansoh received EU approval for Aumolertinib for EGFR-mutated NSCLC, while China's NMPA granted Breakthrough Therapy status to HS-10504 for EGFR C797S-mutated NSCLC.
Jul 09, 2026
New research shows obesity-associated immune checkpoint inhibitor efficacy depends on the diet–gut microbiome axis rather than metabolic dysfunction. Human-to-mouse fecal microbiota transplants from high-BMI donors enhanced ICI efficacy, while a review outlines obesity-related inflammation's role in lung cancer immunotherapy outcomes and biomarkers.
Jul 28, 2026
More than 80% of U.S. physicians use AI in their work. AI is revealing new cardiac biomarkers and speeding drug discovery, with the healthcare AI market projected to reach $505.6 billion by 2033—but studies warn of bias and eroding critical thinking.
Aug 09, 2026
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Aug 08, 2026
Clinical trials show a pancreatic cancer drug nearly doubles survival, a head-and-neck therapy shrinks tumors, and new research explains drug resistance. Cancer mortality is falling in the US and UK.
Jul 19, 2026
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
Aug 08, 2026
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Aug 01, 2026
The American Cancer Society's 2026 statistics show a historic 70% 5-year relative survival rate for all cancers, up from 49% in the mid-1970s. Progress is attributed to earlier detection, targeted therapies, and immunotherapies, though disparities persist for American Indian and Alaska Native populations.
May 05, 2026
TuHURA Biosciences filed an FDA IND for TBS-2025, a VISTA-targeting antibody, plus a menin inhibitor in mutNPM1 r/r AML. Phase 2 targets early Q2 2026 with preliminary Stage 1 results in Q3 2026.
Apr 29, 2026
New studies present SPARK, an AI framework for tumor analysis, a Cell review of liver cancer hallmarks and treatments, and a call for more research into lung cancer in never-smokers, which was the fifth most common cause of cancer death in 2020.
Aug 09, 2026
A first-in-human T-cell therapy showed lasting benefit in children with DIPG and relapsed CNS tumors, while a preclinical mRNA vaccine reduced neuroblastoma tumor size by 70%. Aneuploidy predicted response to olaparib plus irinotecan.
